Imatinib "sandoz" (Imatinib)

Imatinib acts on malignant cells that depend on BCR‑ABL or related tyrosine‑kinase signaling. It is employed in several oncology indications.

• Chronic myeloid leukemia: suppresses leukemic cell proliferation and restores normal blood counts.
• Gastrointestinal stromal tumour: inhibits tumour growth and reduces disease progression.
• Philadelphia chromosome‑positive acute lymphoblastic leukaemia: provides disease control in patients with BCR‑ABL positive disease.

• Imatinib selectively inhibits the ATP‑binding site of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases. By blocking these enzymes, it prevents downstream phosphorylation cascades that drive uncontrolled cell division, thereby reducing proliferation of malignant cells and inducing apoptosis in sensitive tumour populations.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling of the hands, feet, or periorbital area.
• Muscle cramps: intermittent tightening of skeletal muscles.
• Fatigue: persistent lack of energy.
• Diarrhoea: loose stools occurring intermittently.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Neutropenia: marked reduction in white blood cells, increasing infection risk.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: signs of reduced heart function, such as dyspnoea.
• Pulmonary hypertension: elevated pressure in lung arteries.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Tumour lysis syndrome: rapid tumour breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should assess baseline health and monitor patients regularly.

• Blood count monitoring: perform complete blood counts to detect cytopenias.
• Liver function assessment: check hepatic enzymes periodically.
• Cardiac evaluation: review cardiac history and monitor for signs of heart failure.
• Hypersensitivity screening: avoid use in patients with known allergy to imatinib or its excipients.
• Pregnancy considerations: weigh potential benefits against unknown fetal risks.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib can interact with several medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering plasma levels.
• Antacids containing aluminium or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Diuretics (e.g., furosemide): can exacerbate fluid retention.
• QT‑prolonging agents (e.g., quinidine): increase risk of cardiac arrhythmias.
• Vaccines (live attenuated): consider timing to avoid reduced immune response.